ReviewAsia Pacific allergy2026
Allergic reactions in systemic lupus erythematosus: From pathogenic pathways to clinical practice.
Review in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a broad range of clinical presentations. Increasingly, allergic reactions-such as urticaria, drug hypersensitivity, and severe cutaneous adverse reactions-are being recognized as potentially linked to the underlying immune dysregulation in SLE, rather than occurring coincidentally. Objective: This review aimed to examine the immunological overlap between allergy and autoimmunity in SLE and to provide practical guidance on the evaluation and management of allergic manifestations in affected patients. Methods: A narrative review of recent literature was conducted, with a focus on immunopathogenic mechanisms, clinical features, and therapeutic considerations relating to allergy-like symptoms in SLE. Results: Current evidence implicates autoreactive IgE, alterations in Fc receptor signaling, and granulocyte-mediated inflammation as contributors to both allergic and autoimmune processes in SLE. Autoreactive IgE may exacerbate disease activity via plasmacytoid dendritic cell activation and type I interferon pathways. Clinically, allergic symptoms may mimic lupus flares or infections, presenting diagnostic challenges. A structured approach to assessment-considering symptom timing, laboratory markers, and treatment response-can aid differentiation. In select cases, biologic agents such as omalizumab and dupilumab, traditionally used for allergic conditions, may hold therapeutic promise. Conclusion: Allergic manifestations in SLE are often overlooked but carry important diagnostic and therapeutic implications. Greater integration of allergy and autoimmunity frameworks may improve recognition, management, and personalization of care in this complex patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.